Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Volker Diehl Clear advanced filters

  • Hodgkin's lymphoma has become a curable disease successfully treated using dose-escalated BEACOPP chemotherapy regimens pioneered by the German Hodgkin's Lymphoma Study Group. However, the unacceptable side effects of chemotherapy have propagated new therapeutic concepts based on biological characteristics of the disease to be explored. This viewpoint discusses the promises and pitfalls of targeted therapy.

    • Daniel Re
    • Roman K Thomas
    • Volker Diehl
    Reviews
    Nature Clinical Practice Oncology
    Volume: 2, P: 2-3

  • Our understanding of the biology of Hodgkin's lymphoma has improved, in particular the genetic and phenotypic characteristics of malignant cells and the signaling pathways involved in the pathogenesis of this disease. While newer regimens have improved the cure rates of patients with Hodgkin's lymphoma, some are associated with severe acute and long-term toxicities. This comprehensive Review discusses combined modality regimens for treating early-stage disease, approaches used for treating advanced disease and other novel regimens.

    • Andrew M Evens
    • Martin Hutchings
    • Volker Diehl
    Reviews
    Nature Clinical Practice Oncology
    Volume: 5, P: 543-556

  • Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumor-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be a major step towards personalized therapy for patients with Hodgkin lymphoma.

    • Volker Diehl
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 7, P: 301-302

  • The mammalian aryl hydrocarbon receptor (known to sense environmental pollutants) is shown to also have a role as a pattern recognition receptor in sensing bacterial virulence factors, resulting in an antibacterial response and activation of innate and natural defences.

    • Pedro Moura-Alves
    • Kellen Faé
    • Stefan H. E. Kaufmann
    Research
    Nature
    Volume: 512, P: 387-392

  • The optimal treatment for patients with advanced-stage Hodgkin lymphoma is an ongoing controversy. A recent trial seemed to answer some of the important open questions in the field; however, closer examination of the data indicates that the answers are not as clear as they might initially seem.

    • Peter Borchmann
    • Andreas Engert
    • Volker Diehl
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 8, P: 636-637

  • A 48-year-old man presented to his GP with an indolent swelling in his left axillary region. He had also increasingly suffered from night-time sweating and fever. Physical examination and an ultrasound revealed an enlarged lymph node in the left axillary region. The patient was diagnosed with Hodgkin's lymphoma and treated with chemotherapy and involved-field radiotherapy.

    • Beate Klimm
    • Andreas Engert
    • Volker Diehl
    Reviews
    Nature Clinical Practice Oncology
    Volume: 1, P: 51-54

  • Hydrothermal plumes carry dissolved and nanoparticulate iron across vast ocean regions, influencing iron distribution beyond vent systems. This transport is modulated by temperature, pH, microbial transformation, and water-mass dynamics.

    • Solveig I. Bühring
    • Stefanie Böhnke-Brandt
    • Ying Ye
    ReviewsOpen Access
    Communications Earth & Environment
    Volume: 6, P: 1-19